Loading
Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.
Benmelstobart (TQB2450) is a humanised anti-PD-L1 antibody developed by Chia Tai Tianqing, part of Sino Biopharmaceutical. The NMPA approved it in 2024 for first-line treatment of extensive-stage small-cell lung cancer together with the multi-kinase inhibitor anlotinib and platinum-etoposide chemotherapy, on the ETER701 phase 3 trial, which reported longer overall survival than chemotherapy alone. It is the first checkpoint inhibitor approved in a four-drug first-line regimen for this cancer.
Blocks PD-L1 on tumour and immune cells so that T cells are no longer switched off at the tumour. Connects to PD-L1.
1.Benmelstobart binds PD-L1.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Benmelstobart" OR ABSTRACT:"Benmelstobart" OR TITLE:"TQB2450" OR ABSTRACT:"TQB2450") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Benmelstobart, not a curated reading list.
Shares PD-L1, Immune checkpoint inhibitors and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.